These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36777342)

  • 1. The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Liu X; Chen Y; Liu T; Cai L; Yang X; Mou C
    Front Endocrinol (Lausanne); 2023; 14():1115321. PubMed ID: 36777342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    Wei Q; Xu X; Guo L; Li J; Li L
    Front Endocrinol (Lausanne); 2021; 12():635556. PubMed ID: 34220701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Zhang S; Qi Z; Wang Y; Song D; Zhu D
    Front Endocrinol (Lausanne); 2023; 14():1203666. PubMed ID: 37465122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Pan R; Zhang Y; Wang R; Xu Y; Ji H; Zhao Y
    PLoS One; 2022; 17(12):e0279889. PubMed ID: 36584211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Xing B; Zhao Y; Dong B; Zhou Y; Lv W; Zhao W
    J Diabetes Investig; 2020 Sep; 11(5):1238-1247. PubMed ID: 32083798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials.
    Simental-Mendía M; Sánchez-García A; Rodríguez-Ramírez M; Simental-Mendía LE
    Pharmacol Res; 2021 Jan; 163():105319. PubMed ID: 33246172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
    J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
    Li WJ; Chen XQ; Xu LL; Li YQ; Luo BH
    Cardiovasc Diabetol; 2020 Aug; 19(1):130. PubMed ID: 32847602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
    Wang H; Yang J; Chen X; Qiu F; Li J
    Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of sodium-glucose cotransporter-2 inhibitors on myocardial infarction incidence: A systematic review and meta-analysis of randomized controlled trials and cohort studies.
    Huang X; Dannya E; Liu X; Yu Y; Tian P; Li Z
    Diabetes Obes Metab; 2024 Mar; 26(3):1040-1049. PubMed ID: 38086546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.
    Wang X; Fu R; Liu H; Ma Y; Qiu X; Dong Z
    Ann Palliat Med; 2021 Jun; 10(6):6467-6481. PubMed ID: 34118855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hameed I; Hayat J; Marsia S; Samad SA; Khan R; Siddiqui OM; Khan MO; Malik S; Fatima K; Fudim M; Krasuski RA
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102111. PubMed ID: 36931466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis.
    Masson W; Lavalle-Cobo A; Nogueira JP
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
    Mazidi M; Rezaie P; Gao HK; Kengne AP
    J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of combination therapy with sodium-glucose cotransporter 2 inhibitors and renin-angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis.
    Tian B; Deng Y; Cai Y; Han M; Xu G
    Nephrol Dial Transplant; 2022 Mar; 37(4):720-729. PubMed ID: 33605424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bae JH; Park EG; Kim S; Kim SG; Hahn S; Kim NH
    Sci Rep; 2019 Sep; 9(1):13009. PubMed ID: 31506585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials.
    Sánchez-García A; Simental-Mendía M; Millán-Alanís JM; Simental-Mendía LE
    Pharmacol Res; 2020 Oct; 160():105068. PubMed ID: 32652200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Mori Y; Duru OK; Tuttle KR; Fukuma S; Taura D; Harada N; Inagaki N; Inoue K
    J Clin Endocrinol Metab; 2022 Dec; 108(1):221-231. PubMed ID: 36217306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.